SinoMab BioScience 3681.HK · HKD

Its shares trade on HKEX under the ticker 3681.HK. It has been listed since 12 November 2019. In the fiscal year to 31 December 2024, it reported revenue of CN¥2.0m and a net loss of CN¥185.1m. At that date it held total assets of CN¥753.1m and shareholders' equity of CN¥192.9m.

SinoMab Bioscience Ltd. operates as a clinical stage biopharmaceutical company. The company employs 112 full-time employees The company went IPO on 2019-11-12. The firm primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The firm is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Shui On LeungChairman of the Board, Chief Executive Officer, since 2003CN¥4.4m
• Mr. Jianping HuaChief Financial Officer
• Mr. Wang ShanchunExecutive Director, since 2024
• Dr. Ka Wa CheungResearch Scientist
• Dr. Ming Hon YauResearch Project Manager
• Dr. Kwan Yin SiuResearch Scientist
• Dr. Lixin Zhang AubersonChief Medical Officer
• Ms. Yuk Yin ChowCompany Secretary
• Dr. Haigang ChenNon-Executive Director
• Mr. Xun DongNon-Executive Director
• Dr. Zhang JianminNon-Executive Director
• Ms. Xiaosu WangNon-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.